Shenzhen Hepalink Pharmaceutical Group Co's quarterly market cap
declined
from Sep. 2023 (HK$5,972 Mil) to Dec. 2023 (HK$5,253 Mil) and
declined
from Dec. 2023 (HK$5,253 Mil) to Mar. 2024 (HK$4,079 Mil).
Shenzhen Hepalink Pharmaceutical Group Co's annual market cap
declined
from Dec. 2021 (HK$11,944 Mil) to Dec. 2022 (HK$8,011 Mil) and
declined
from Dec. 2022 (HK$8,011 Mil) to Dec. 2023 (HK$5,253 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Shenzhen Hepalink Pharmaceutical Group Co's Enterprise Value for Today is HK$17,079 Mil.
Shenzhen Hepalink Pharmaceutical Group Co Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Shenzhen Hepalink Pharmaceutical Group Co Market Cap Chart
Shenzhen Hepalink Pharmaceutical Group Co Annual Data
Competitive Comparison of Shenzhen Hepalink Pharmaceutical Group Co's Market Cap
For the Drug Manufacturers - Specialty & Generic subindustry, Shenzhen Hepalink Pharmaceutical Group Co's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shenzhen Hepalink Pharmaceutical Group Co's Market Cap Distribution in the Drug Manufacturers Industry
* The bar in red indicates where Shenzhen Hepalink Pharmaceutical Group Co's Market Cap falls into.
Shenzhen Hepalink Pharmaceutical Group Co Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shenzhen Hepalink Pharmaceutical Group Co (HKSE:09989) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Shenzhen Hepalink Pharmaceutical Group Co Market Cap Related Terms
Thank you for viewing the detailed overview of Shenzhen Hepalink Pharmaceutical Group Co's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Shenzhen Hepalink Pharmaceutical Group Co (HKSE:09989) Business Description
Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based company engaged in biopharmaceutical production, biopharmaceutical services, biopharmaceutical trading and biopharmaceutical research and development. The company distributes its products both in the domestic and overseas markets. The Group mainly operates three main business segments, including Finished dose pharmaceutical products business; Active pharmaceutical ingredients; CDMO business and Others. Geographical presence of company is in Hong Kong, United States of America, Europe, Mainland China and Other countries. Majority of the company's revenue comes from USA and Europe.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:09989 has been successfully added to your 